Resources for Healthcare Professionals
This section of CredibleMeds® includes tools to assist physicians, nurses, pharmacists and other healthcare professionals who play central roles in medication safety.
QT Drugs List: This portal includes QTdrugs.org, a list of drugs categorized by their potential to cause QT prolongation and/or torsades de pointes (TdP). Click on a drug and see if the FDA-approved label mentions contraindicated concomitant meds or recommends ECG monitoring.
Categories of TdP risk for drugs on the QTdrugs List:
- Drugs with known risk of TdP
- Drugs with possible risk of TdP
- Drugs with conditional risk of TdP - i.e., drugs that can cause TdP under certain conditions or which create conditions that foster TdP
Additional drug information is provided when you click on a drug name:
- Information on routes of administration.
- PubMed Links: Automatically search the National Library of Medicine's PubMed databease for articles on the drug's ability to prolong the QT intervals and/or cause torsades de pointes (TdP).
- FDA label: Information on whether the drug's label has a "black box" warning for QT/arrhythmia, mentions prolonged QT prolongation or TdP, mentions contraindicated concomitant drugs or recommends ECG monitoring.
Drugs can be displayed by TdP risk category and sorted by: Generic Name, Brand Name, Risk Category, Pharmacologic Class, and Therapeutic Use.
List of Drugs to be Avoided (DTA) in patients with congenital Long QT (includes all on the QTdrugs List plus drugs with Special Risk due to their adrenergic actions.The DTA list can be exported by all registrants as a PDF file and printed.
QTFactors.org - Clinical Factors Associated with Prolonged QTc and/or TdP: This is a list of clinical factors or conditions that have been associated with prolonged QTc and/or Torsades de Pointes (TdP) in the scientific literature.
OncoSupport™ Drug List: This is a printable list of the drugs that are on the QTdrugs List and which are often prescribed for patients with cancer. It includes designation of each drug's TdP risk category.
A pocket summary of the clinical effects ofantiarrhythmc drugs and their actions on the ECG, ion channels and membrane receptors. Contributed by Romero, K and Woosley, RL, Chapter 18, Clinical Pharmacology of Antiarrhythmic Drugs, Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease, Fourth Edition edited by E.M. Antman and M.S. Sabatine, 2012.